Fosun Pharma Unit Gets China Nod for Two Drug Registration Applications
MT Newswires Live
Sep 15
Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) unit Jinzhou Avanc Pharmaceutical obtained approvals for two drug registration applications from China's National Medical Products Administration, a Monday Hong Kong bourse filing said.
The regulator approved the application for the Famotidine Injection for the indication of gastrointestinal bleeding caused by peptic ulcers, as well as gastric and duodenal mucosal erosive bleeding.
The second application was approved for an additional indication of the Fovinaciclib Citrate Capsules to treat locally advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine therapy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.